Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Parallel-group, Multi-center Study to Investigate the Pharmacodynamics and Pharmacokinetics of a Combined Oral Contraceptive Containing Levonorgestrel (LNG) and Ethinylestradiol (EE) When Given Together With Vilaprisan Over 3 Months in Healthy Women of Reproductive Age

Trial Profile

A Randomized, Double-blind, Parallel-group, Multi-center Study to Investigate the Pharmacodynamics and Pharmacokinetics of a Combined Oral Contraceptive Containing Levonorgestrel (LNG) and Ethinylestradiol (EE) When Given Together With Vilaprisan Over 3 Months in Healthy Women of Reproductive Age

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Dec 2018

At a glance

  • Drugs Vilaprisan (Primary) ; Ethinylestradiol/levonorgestrel
  • Indications Endometriosis; Uterine leiomyoma
  • Focus Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 12 Nov 2018 Planned End Date changed from 23 Nov 2018 to 21 Dec 2018.
    • 10 Oct 2018 Planned End Date changed from 1 Nov 2018 to 23 Nov 2018.
    • 10 Jul 2018 Planned End Date changed from 1 Oct 2018 to 1 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top